EMA Lapsed: Exalief (eslicarbazepine acetate) — BIAL - Portela Ca, S.A.

View source ↗

Summary

EMA status indicates Exalief (eslicarbazepine acetate) has lapsed in Europe.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Exalief (eslicarbazepine acetate)

Snippet

Status: Lapsed. Therapeutic area: Epilepsy. MAH: BIAL - Portela Ca, S.A.. Decision date: 21/04/2012